Abstract | Chemoprevention of lung carcinogenesis is one approach to controlling the epidemic of lung cancer caused by cigarette smoking. The target for chemoprevention should be the activities of the multiple carcinogens, toxicants, co-carcinogens, tumour promoters and inflammatory compounds in cigarette smoke. At present there are many agents, both synthetic and naturally occurring, that prevent lung tumour development in well-established animal models. It seems likely that logically constructed mixtures of these agents, developed from the ground up, will be necessary for the prevention of lung carcinogenesis.
Lung cancer kills more than 3,000 people every day and is the leading cause of cancer death. About 90% of this incredible toll is due to cigarette smoking. Clearly, we must continue our successful efforts in tobacco control, which have resulted in a substantial reduction in smoking prevalence in many countries. But there are still 1.3 billion smokers in the world and wealthy multinational tobacco companies continue to introduce cancer-causing products designed to entice teenagers into a lifetime of nicotine addiction. Although 70% of smokers attempt to quit each year, less than 5% succeed 1 , and the average success rates at 6 months after quitting, even with the most advanced smoking-cessation programmes, hover around 25% 2 .
In recent years, the rate of decrease in the prevalence of adult smoking in the United States has slowed significantly 3 , remaining at about 20% from 2004 to 2007 (REF. 4 ). This plateau has been observed even in countries such as Ireland, which has a prominent tobacco control programme (for example, comprehensive smoke-free worksite policies, high cigarette prices and bans on tobacco advertising and promotion) 5 . This reduced rate of decline in smoking has been attributed to a plateau in smokingcessation success 3 , leading some researchers to think that the remaining population of smokers is hardcore and are either unwilling or unable to quit 6 . An appreciable number of these smokers may be experiencing mental health disorders 5 . The addicted smokers who fail and the ex-smokers who have succeeded in quitting are at high risk for lung cancer, and we must do something to help prevent this devastating disease, which has a 5-year survival rate of only 15%. Chemoprevention of lung carcinogenesis is one way forward. Although the cardiovascular community has identified high-risk individuals with biomarkers such as cholesterol and C reactive protein, and successfully treated them with preventive statins 7 , we in cancer research have yet to succeed in developing an effective lung carcinogenesis chemopreventive agent or strategy. The theme of this article is that a successful lung carcinogenesis chemopreventive agent will target tobacco smoke carcinogens and toxicants, the cause of lung cancer in smokers and ex-smokers, and that a successful strategy will integrate chemoprevention into the treatment portfolio of the addicted smoker as well as being available for the confirmed ex-smoker.
Treat lung carcinogenesis, not lung cancer
In chemoprevention, we aim to treat lung carcinogenesis, not lung cancer 8 . Lung carcinogenesis is barely in the vocabulary of the cancer research community, and certainly not in that of the lay community. The distinction is crucial. Lung cancer is the end result of lung carcinogenesis. Treatment of lung cancer is usually ineffective because a malignant tumour is discovered at a late stage. Treating lung carcinogenesis has the potential to prevent this disease.
How can we treat lung carcinogenesis? As 90% of lung carcinogenesis is due to tobacco smoke exposure, our target must be the carcinogenic activity of tobacco smoke. In previous articles, we have presented a conceptual model for tobacco smoke-induced lung carcinogenesis 9, 10 
. This model indicates that, in our treatment of lung carcinogenesis, we would be wrong to focus on a single molecular pathway, because multiple pathways are altered. others have come to similar conclusions 11 . We need to focus on the cause of the various aberrant biological pathways in lung carcinogenesis: the activities of tobacco smoke. of course, removing tobacco smoke exposure is the ideal method for preventing lung carcinogenesis, but for the reasons discussed above, this is only partially successful.
What are the activities of tobacco smoke that are crucial in lung carcinogenesis? First and foremost are the lung carcinogens. of the more than 60 established carcinogens in cigarette smoke, there are at least 20 credible lung carcinogens 9, 10, 12 . These occur in both the gas phase and the particulate phase of tobacco smoke. The gas phase constituents include 1,3-butadiene, ethylene oxide, benzene and aldehydes. The particulate phase constituents include polycyclic aromatic hydrocarbons (PAHs), the best known of which is benzo[a]pyrene (BaP), and tobacco-specific nitrosamines such as the potent lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Consistent with the presence of these carcinogens, both the gas phase and the particulate phase of tobacco smoke can induce lung tumours in rodents upon exposure by inhalation 13 .
Second are the tumour promoters, co-carcinogens and toxicants, which have various deleterious activities. Tumour promoters are not carcinogenic themselves, but they enhance the activity of carcinogens when given subsequently. The tumour-promoting activities of tobacco smoke and its condensate have been clearly demonstrated through administration both by inhalation and by application to mouse skin 14, 15 . These tumour promoters are only partially characterized, but extensive data indicate that they are found mainly in the weakly acidic fraction of tobacco smoke condensate 16 . Co-carcinogens are also not carcinogenic themselves, but they enhance the activity of carcinogens when given concurrently. Catechol, methyl catechols and certain PAHs are wellestablished co-carcinogens in tobacco smoke, as indicated by studies on mouse skin 15 . one of the main toxicants in cigarette smoke, with a demonstrated relationship to lung carcinogenesis, is acrolein. Although it is not strongly carcinogenic itself, acrolein is highly toxic to cilia of the lung, thus impeding clearance of tobacco smoke constituents 17 . Acrolein also reacts directly with DNA and protein to produce adducts with potentially important consequences [18] [19] [20] . other toxicants in tobacco smoke include nitric oxide and poorly characterized free radicals, which may contribute to tumour promotion or co-carcinogenesis by causing oxidative damage.
Third are the inflammatory agents. Several proinflammatory changes have been observed in smokers' lungs, and inflammation is closely associated with tumour promotion and activation of factors such as nuclear factor-ĸB (NK-ĸB) [21] [22] [23] [24] . Inflammation has a role in smoking-associated chronic obstructive pulmonary disease (CoPD) 25 , and CoPD (especially emphysema) is, in turn, an independent risk factor for lung cancer 26 . The specific agents in cigarette smoke responsible for inflammation are poorly defined, but the potential roles of oxidants and reactive aldehydes such as acrolein have been discussed 20, 25 . It is important to keep in mind that exposure to all agents in cigarette smoke is simultaneous; thus, concepts such as tumour initiation and tumour promotion may be artificial or even irrelevant.
It is apparent to us that a mixture of chemopreventive agents will be necessary to counteract these three complex activities. This mixture should be developed from the ground up, by first determining the efficacy of individual agents and then assessing their chemopreventive activities when tested as a mixture. Chemopreventive agents have been classified into two broad groups: blocking agents that prevent the interaction of carcinogens with DNA and suppressing agents that prevent downstream effects following exposure to carcinogens 27 . These definitions are still useful, and it is likely that an effective mixture would contain as a minimum an agent with each type of activity. Two crucial requirements for any chemopreventive agent or mixture are efficacy and lack of toxicity. one must demonstrate efficacy in an animal model, or preferably models, before chemopreventive agents should be seriously considered for use in people. Lack of toxicity is also crucial, or clinical usefulness will be compromised.
At a glance
• Lung cancer kills more than 3,000 people every day, and most of this toll is due to cigarette smoking. Although tobacco control is clearly the most desirable way to prevent lung cancer, cigarette smoking is addictive and, despite considerable success to date, there are still more than 1 billion smokers in the world who, along with ex-smokers, are at high risk for lung cancer. Chemoprevention of lung carcinogenesis is one way forward in the control of this devastating disease.
• In considering chemoprevention, it is crucial that we focus on treating lung carcinogenesis, not lung cancer. The disease process is carcinogenesis.
• Lung carcinogenesis is caused by numerous carcinogens in cigarette smoke, along with tumour promoters, co-carcinogens, toxicants and inflammatory agents. In devising chemoprevention strategies, these agents should be our targets. Targeting a single pathway in lung carcinogenesis is not likely to be successful.
• Because there are numerous carcinogenic and toxic constituents of tobacco smoke, we need to develop a mixture of chemopreventive agents to counteract them. This mixture should be developed from the ground up, using animal models to demonstrate efficacy without appreciable toxicity.
• Well-established animal models are available for evaluating chemopreventive efficacy against lung carcinogenesis. The most commonly used model by far is the carcinogen-treated A/J mouse, which develops similar adenocarcinoma to that seen in humans.
• Many agents have shown chemopreventive efficacy against lung carcinogenesis in animal models. Examples include phenethyl isothiocyanate, indole-3-carbinol, myo-inositol, green and black tea and its constituents, silibinin, glucocorticoids, difluoromethylornithine, oleanane and ursane triterpenoids, non-steroidal anti-inflammatory drugs, farnesyltransferase inhibitors, organoselenium compounds and others. Some mixtures of these agents also demonstrate efficacy.
• There have been no successful lung carcinogenesis clinical trials. Current trials include examinations of some of the agents listed above, but no mixtures.
• In chemoprevention of lung carcinogenesis, we must target current smokers, smokers transitioning to quitting and ex-smokers. Although cessation is clearly the best way to decrease the probability of the onset of lung cancer, most smokers cannot quit, even after many tries. It would be unethical not to offer these people effective agents.
Pre-clinical evaluation of agents
In keeping with the theme of inhibiting the carcinogenic and toxic activities of tobacco smoke, the ideal animal model would use tobacco smoke itself as the carcinogen. Unfortunately, this is not as simple as might be expected. The use of rodent models for inhalation of tobacco smoke poses many difficulties 13 
. Despite the limitations, one practical model using strain A/j mice has been described 28 . A/j mice develop lung tumours with age. Lung tumour multiplicity is significantly and reproducibly increased by carcinogen treatment 29, 30 . The cigarette smoke inhalation protocol leads to a reproducible increase in lung tumour multiplicity and, in some cases, lung tumour incidence in these mice 28 . However, the increase in lung tumour multiplicity -from about 0.5-1 lung tumours per mouse in controls to 1.1-2.8 lung tumours per mouse in the mice treated with cigarette smoke -although significant, is small. This creates severe practical problems when using this model for chemoprevention studies. Several chemoprevention experiments that used this smoke inhalation assay with small groups of animals have been reported, but most of the results were statistically insignificant, with the exception of a mixture of dexamethasone and myo-inositol 28 . Several other mouse strains have been used in experiments of similar design, but the tumorigenic response to cigarette smoke was generally weak 31 . By far the most commonly used model for evaluating chemopreventive agents is the carcinogen-treated A/j mouse. The tumours induced by carcinogens have morphological, histological and molecular features that are similar to human lung adenocarcinoma 32 . The susceptibility of the A/j mouse to lung tumour development has been attributed to the pulmonary adenoma susceptibility 1 (Pas1) gene, which is tightly linked to the Kras oncogene 33 . Four carcinogens -BaP, NNK, ethyl carbamate (urethane) and vinyl carbamate -have been used extensively for tumour induction in chemoprevention experiments
. BaP and NNK are widely viewed as important lung carcinogens in cigarette smoke. Urethane is the classic carcinogen used for lung tumour induction in A/j mice 34 , whereas vinyl carbamate is its proximate carcinogenic metabolite. Urethane has been reported as a constituent of cigarette smoke, but only sporadically, and vinyl carbamate has not been analysed in cigarette smoke or in smokers as a metabolite. The doses of pure carcinogens used in these studies are thousands of times higher than the amounts present in cigarette smoke. In studies with these carcinogens, statistically meaningful results can be obtained with only 15 mice per group. This approach is highly practical for examining potential chemopreventive efficacy. The chemopreventive agent can be given during carcinogen treatment, after carcinogen treatment or throughout the experiment to decipher its potential at different stages of the carcinogenic process. These assays are relatively rapid and inexpensive. A variation on the use of single carcinogens is the use of BaP and NNK together, given in multiple doses 35 . The object of this design is to more closely approximate the effects of cigarette smoke by using a mixture of two of its important carcinogens, and also to allow intervention with chemopreventive agents at various points during carcinogen treatment to reflect, to some extent, the situation in smokers who are transitioning to quitting 36 . This aspect has been almost completely overlooked in previous efficacy studies. FIGURE 1 shows a typical design for such a study. Treatment with chemopreventive agents in the diet may be scheduled to begin 1 day after the fourth carcinogen treatment (or at other intervals if desired), to approximate the transitioning smoker, or 1 week after the last carcinogen treatment, to mimic the situation in ex-smokers 37 .
Although the A/j mouse is a widely used and convenient model for the induction of adenocarcinoma and investigation of the effects of chemopreventive agents, a similar model for induction of squamous cell carcinoma became available only recently. Application of N-nitrosotris-chloroethylurea (NTCU) to the skin of Swiss mice produced various tumours, including squamous cell carcinoma of the lung 38 . In another study, treatment of eight inbred strains of mice with NTCU by skin painting produced squamous cell carcinoma of the lung in a strain-specific manner, with A/j, NIH Swiss and SWr/j being the most susceptible strains (tumour incidence was 75-100%) 39 . This model should be useful for investigating chemoprevention of squamous cell carcinoma of the lung. However, it should be noted that NTCU is a synthetic carcinogen that is not present in cigarette smoke.
Treatment of F-344 rats with NNK results in the production of lung adenoma and adenocarcinoma, and this model has been used to investigate chemopreventive agents, although less frequently than the A/j mouse 40 . rat studies are more expensive than mouse experiments because 2 years are required for the development of lung tumours. The F-344 rat is far less susceptible to lung tumour induction than the A/j mouse, and there is virtually no background incidence of lung tumours. The rat model is an attractive one for confirming lung chemoprevention activity observed in mice 40 . In another approach, the induction and modification by chemopreventive agents of preneoplastic lesions of the lung induced by intratracheal instillation of NNK in Wistar rats has been described 41 . A hamster model of neuroendocrine lung carcinogenesis involving hyperoxic lung
Box 1 | A conceptual model for tobacco smoke-induced lung carcinogenesis
In this widely accepted model, people become addicted to nicotine in cigarette smoke, usually at a young age, when peer pressure and advertising cause them to experiment with cigarettes. Nicotine is not a carcinogen, but each puff of each cigarette delivers a mixture of more than 60 established carcinogens, along with toxicants, tumour promoters, co-carcinogens, oxidants, free radicals and inflammatory agents. The carcinogens and their metabolites bind to DNA, resulting in DNA adducts and subsequent somatic mutations. When these mutations occur in crucial genes, such as oncogenes and tumour suppressor genes, the result is a loss of normal cellular growth control mechanisms, genomic instability and cancer. A recent study validates this model: DNA sequencing of 623 cancer-related genes revealed more than 1,000 somatic mutations in 188 human lung adenocarcinomas, and 26 of these genes, including the tumour suppressor gene TP53 and the oncogene KRAS, were mutated at significantly higher frequencies. Alterations were commonly observed in genes of the MAPK signalling, TP53 signalling, Wnt signalling, cell cycle and mTOR pathways 131 . The multiple mutations caused by tobacco smoke carcinogens are also consistent with the concept of field cancerization.
injury and treatment with NNK has also been used, as has an adenocarcinoma model initiated by NNK treatment of hamsters without hyperoxia 42 .
Preclinical studies identify effective agents Naturally occurring and synthetic agents that prevent lung carcinogenesis in laboratory animals are summarized in TABLES 1,2, and structures of individual compounds are shown in FIG. 2. our purpose here is to present an overview of the currently effective agents without a detailed evaluation of efficacy and potential toxicity, which is beyond the scope of this review. We focus on agents that have been the subject of relatively recent investigations, mainly in this century. Previous reviews have summarized data from earlier studies 40, 43, 44 . The diversity of chemical structures in FIG. 2 reflects the numerous targets that have been investigated for chemoprevention of lung carcinogenesis. This is appropriate because cigarette smoke causes multiple alterations in crucial growth control pathways. Ultimately, rationally constructed mixtures of some of these agents will undoubtedly be needed for successful chemoprevention.
Numerous studies carried out over the past three decades clearly demonstrate that isothiocyanates inhibit lung carcinogenesis in animal models 45 . Phenethyl isothiocyanate (PeITC) and its metabolite, the N-acetylcysteineconjugated form PeITC-NAC, have been investigated in the most detail and, among isothiocyanates, overall have the best properties consistent with chemoprevention of lung carcinogenesis 36, [45] [46] [47] [48] . PeITC and PeITC-NAC are particularly effective against carcinogenesis by NNK, as shown in studies in both rats and mice, but they are less effective against lung carcinogenesis by PAH or in the post-carcinogen treatment period. Benzyl isothiocyanate (BITC) is a highly effective inhibitor of PAH carcinogenesis 49 . In animal studies, PeITC or PeITC-NAC inhibited the metabolic activation of NNK, suggesting that, in smokers and in those transitioning to quitting, these agents could potentially be used to neutralize the lung carcinogenic effects of NNK. PeITC is a strong inhibitor of cytochrome P450 2A13 (K i = 30 nm), the most effective catalyst of NNK metabolic activation in the human respiratory tract 50 , and BITC has the potential to neutralize carcinogenesis by PAH. Thus, tobacco smoke carcinogens are targets of isothiocyanates, but these compounds also have some favourable downstream effects on pathways involved in apoptosis and proliferation of transformed cells 51 . Similarly to PeITC, 8-methoxypsoralen inhibits cytochrome P450 2A enzymes and effectively inhibits NNK-induced mouse lung tumorigenesis [52] [53] [54] . Wattenberg and estensen were was the first to demonstrate that myo-inositol is an effective inhibitor of lung carcinogenesis by both NNK and BaP 55, 56 . Myo-inositol inhibited lung carcinogenesis induced by a mixture of BaP plus NNK when given during the carcinogen treatment period or afterwards. This suggests that myo-inositol has potential efficacy in smokers and ex-smokers 57 . There seem to be virtually no toxic effects associated with myo-inositol treatment, as recently confirmed in a Phase I clinical trial in which the maximum tolerated dose was 18 g per day 58 . Although the main mechanisms through which myo-inositol inhibits lung carcinogenesis are not clear, a recent study demonstrates that it inhibits activation of the serine/threonine kinase Akt 37 . Tobacco smoke carcinogens and the biological effects that they elicit are targets of myo-inositol. many epidemiological studies demonstrate that consumption of cruciferous vegetables is associated with a lower risk of lung cancer, and this effect seems to be particularly strong in people with glutathione S-transferase-µ1 (GSTM1) and glutathione S-transferase-θ1 (GSTT1) null genotypes, indicating a diet-gene interaction 59 . The unique property of cruciferous vegetables is the presence of glucosinolates which, upon consumption of the raw vegetable (or to a lesser extent, the cooked vegetable), yield isothiocyanates and indole-3-carbinol, among other products 60 . The chemopreventive properties of isothiocyanates, as noted above, are consistent with the observation of reduced cancer risk. However, among the major products to which humans are exposed when they consume common cruciferous vegetables are indole-3-carbinol and its dimer, di-indolyl methane (DIm), which forms in the stomach owing to the low pH of the gastric
Box 2 | Problems with rodent models of smoke inhalation
Rodents are obligatory nose breathers with complex nasal structures that are different from those in humans, leading to different deposition patterns in rodents compared with humans. Rodents do not inhale tobacco smoke voluntarily the way humans do, but rather adopt shallow breathing patterns and avoidance reactions. The exposure systems that have been used are problematic. Nose-only exposure systems require extensive handling, whereas whole-body exposure systems result in deposition of particles on the pelt and oral exposure through grooming. Exposure in these systems can cause stress and lack of weight gain. Lung tumours have been induced by cigarette smoke exposure in both rats and mice, but lengthy whole-body exposures are required and the experiments use highly specialized inhalation facilities that are not widely available 132, 133 .
Box 3 | Typical procedures for inducing lung tumours in A/J mice

BaP (benzo[a]pyrene)
A/J mice were maintained on a semi-synthetic diet and, at 9 weeks of age, were treated with 2 mg (7.9 μmol) BaP in cottonseed oil by gavage 56 . This was repeated 4 days and 7 days after the initial dose. The study was terminated 21 weeks after the final dose, causing about 13 lung tumours per mouse. A disadvantage is the induction of forestomach tumours, which become large after 21 weeks and may kill the animals before the scheduled termination. (methylnitrosamino)-1-(3-pyridyl)-1-butanone) A/J mice were maintained on a semi-synthetic diet and, at 7 weeks of age, were treated with a single dose of 2 mg (10 μmol) NNK by intraperitoneal injection. The experiment was terminated 16 weeks later, producing 8-12 lung tumours per mouse and no forestomach tumours. Use of an 'open formula' diet significantly decreases tumour multiplicity 134, 135 . The lung tumours observed at 16 weeks are all adenomas; adenocarcinomas are observed 40-50 weeks after treatment 136 .
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Urethane
Mice at 6 weeks of age were given a single interperitoneal injection (1 mg per gram of body weight, or about 225 μmol) of urethrane in saline. About 30-50 lung adenomas per mouse were observed 15 weeks after injection. Lung adenocarcinoma appeared 32 weeks after injection 77 .
Vinyl carbamate
Mice at 7-8 weeks of age were injected intraperitoneally with two doses (0.32 mg, 3.6 μmol) in saline, 1 week apart. The mice were killed 16 weeks later and had 16 lung tumours per mouse, all of which were described as invasive carcinomas 90 , although in another study the carcinoma yield was apparently much lower 79 . [60] [61] [62] . Indole-3-carbinol and DIm are both effective inhibitors of lung carcinogenesis by BaP plus NNK, and the effects of indole-3-carbinol have been observed both in the carcinogen treatment and post-carcinogen treatment phases [63] [64] [65] . Indole-3-carbinol enhances the hepatic clearance of NNK and decreases levels of some crucial proteins, such as hypoxia-inducible factor-1α (HIF1α) and fatty acid synthase (FAS), in mouse lung tumours 66 . Whereas indole-3-carbinol seems to have several targets, specific inhibitors of FAS, such as C75, have chemopreventive activity in mouse models of lung carcinogenesis 67 .
A large body of experimental data shows that tea and its constituents inhibit lung carcinogenesis in laboratory animals 68, 69 . Green tea, popular in Asia, is 30-40% (weight for weight; w/w) composed of catechins such as (-)-epigallocatechin-3-gallate (eGCG), whereas black tea, more popular in Western nations, is processed in such a way as to release phenol oxidase, thus oxidizing the catechins to oligomers such as theaflavins and to polymers called thearubigins 68, 69 . A standardized green tea polyphenol preparation called 'polyphenon e' has also been used for chemoprevention studies. In the NNK lung carcinogenesis model, and in other models, green tea, black tea and their decaffeinated versions, as well as polyphenon e, significantly inhibited tumour development 68, 69 . Inhibition has also been seen in models of various other lung carcinogens, including BaP 68, 69 . Both black tea and polyphenon e inhibited the progression of adenoma to adenocarcinoma in mice treated with NNK 70 , and polyphenon e inhibited progression to large carcinoma in BaP-treated mice 71 . Several mechanisms have been reported for the inhibitory properties of tea and its constituents, including induction of phase II enzymes, decreased oxidative damage, induction of apoptosis and inhibition of cell proliferation 68, 69 . Synergistic inhibition was observed with a combination of polyphenon e and atorvastatin 72 . Another beverage with chemopreventive activity against lung carcinogenesis is kava, a root extract consumed widely by South Pacific islanders. Kava inhibited lung tumorigenesis when given in the carcinogen treatment or post-carcinogen treatment phases 73 . A Chinese herbal mixture called Antitumour B, also known as Zeng Sheng Ping, is made from six plants and has a history of safe clinical use. Antitumour B significantly decreased tumour multiplicity and tumour load in mice treated with BaP 74 . Ginseng, another traditional medicine used in Asia, also suppressed lung tumour multiplicity in mice treated with BaP 75 . Similarly, pomegranate fruit extract is another plant-based agent with considerable inhibitory activity against lung tumorigenesis 76 . Silibinin, a flavonone from milk thistle, is structurally related to tea polyphenols. It has been used as a dietary supplement to improve liver function and as an anti-hepatotoxic drug 77 , apparently with low toxicity. Silibinin added at concentrations of 0.033-1% (w/w) to the diet of mice treated with urethane significantly decreased lung tumour incidence recorded 20 weeks later 77 . Silibinin treatment decreased proliferation markers and tumour microvessel density, as well as lung tumour expression of vascular endothelial growth factor, inducible nitric oxide synthase and the cyclooxygenase CoX2, which are all thought to be involved in inflammation and tumour progression 77 . Silibinin (0.05-0.1% w/w in the diet) given before BaP had no effect on tumour multiplicity or tumour load 78 . Thus, tumour promotion and inflammation are targets of silibinin.
Dexamethasone and budesonide are glucocorticoids, compounds that bind to and activate the cytosolic glucocorticoid receptor. Dexamethasone inhibits the promotion stage of carcinogenesis in various models and was first applied in lung carcinogenesis studies by estensen and Wattenberg 55 . In further studies, it demonstrated good activity in various mouse models, and particularly in combination with myo-inositol 56, [79] [80] [81] . This combination is the only one reported to successfully inhibit lung tumorigenesis in the tobacco smoke inhalation model described by Witschi 81 . Similarly, budesonide shows good activity in various mouse models [82] [83] [84] [85] . A potentially important approach to chemoprevention uses inhaled budesonide, which lowers the risk of systemic side effects yet maintains excellent efficacy at low doses 86 . This approach was also successful when combined with dietary myo-inositol in mouse models 86 . Difluoromethylornithine (DFmo), an inhibitor of the tumour-promoting protein ornithine decarboxylase, is also effective as a chemopreventive agent against squamous cell carcinoma when given by inhalation to hamsters 87 . oleanane and ursane triterpenoids are pentacyclic compounds that are derived biosynthetically from squalene. Sporn, Gribble and co-workers have targeted inflammation with diverse structural analogues that inhibit inducible nitric oxide synthase and CoX2 and are also phase II enzyme inducers 88, 89 . CDDo-methyl ester and CDDo-ethyl amide, which are derived from the oleanane triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid, as well as CDDo are potent inhibitors of vinyl carbamate-induced mouse lung carcinogenesis in the post-carcinogen phase 90 . rexinoids, selective ligands for the retinoid X receptors rXrα, rXrβ and rXrγ, with anti-inflammatory activity are also effective. Targretin and NrX194204 have shown activity in the post-carcinogen phase 91, 92 . rapamycin, a natural product isolated from Streptomyces hygroscopicus, is an inhibitor of mTor that acts downstream of Akt and PI3K in a pathway commonly activated in lung carcinogenesis. rapamycin decreased lung tumour load, but not tumour multiplicity, in a mouse anti-progression protocol in which BaP was the carcinogen 75 . Inflammation has also been targeted by non-steroidal anti-inflammatory drugs (NSAIDs) such as sulindac. CoX enzymes have a key role in the synthesis of prostanoids involved in inflammation. CoX1 is constitutively expresed, whereas CoX2 is inducible. once induced, CoX2 is constitutively expressed as tumours progress. CoX2 expression is observed in human nonsmall cell lung cancer, and expression of both CoX1 and CoX2 has been observed in normal lung tissue and lung tumours in mice 22, 93, 94 . Sulindac and its sulphone metabolite along with aspirin and several other CoX inhibitors are effective chemopreventive agents in NNK-treated mice [95] [96] [97] [98] [99] . However, although the specific CoX2 inhibitor celecoxib reduced pulmonary inflammation, it had no effect on lung tumour multiplicity in A/j mice 99 . Interest in CoX2 inhibitors has been lessened because of their cardiovascular toxicity 22 . Lipoxygenase inhibitors, which inhibit the formation of leukotrienes involved in inflammation, have also been effective; A-79175 and mK-866 are two such compounds that are known to inhibit lung carcinogenesis 100, 101 . Human lung adenocarcinomas commonly have a mutated KRAS oncogene 102 . The ras proteins are GTPases involved in the regulation of signal transduction pathways that control proliferation and apoptosis. ras proteins are typically farnesylated to become active, so farnesyltransferase inhibitors are natural agents for chemoprevention. Several farnesyltransferase inhibitors, including r115777, FTI-276 and perillyl alcohol, have shown activity in BaP-or NNK-induced mouse lung tumour models 103, 104 . organoselenium compounds have emerged as an interesting class of agents. When given during or after administration of BaP and NNK, 1,4-phenylenebis(methylene)selenocyanate (XSC), a non-toxic organoselenium compound, inhibits lung carcinogenesis in mice and has some favourable effects on phase I and phase II enzymes 105, 106 . XSC also reduced the expression of CoX2, NF-ĸB and cyclin D1 in lung cells 107 . In contrast to XSC, selenium-enriched yeast had no effect on NNK-induced mouse lung tumorigenesis 108 .
Another interesting class of organoselenium compounds is the selenazolidine carboxylic acids, prodrugs of selenocystine, which inhibit NNK-induced lung tumorigenesis 109, 110 . Deguelin is an inhibitor of the PI3K-Akt pathway and decreases the expression of CoX2. It was an effective inhibitor of mouse lung tumorigenesis induced by BaP plus NNK in both the carcinogen administration and post-carcinogen administration phases 78, 111 . There is concern about potential toxic effects of deguelin, and structural variants are being examined 112 . Another target for chemoprevention is endogenous DNA hypermethylation, which can inhibit transcription of tumour suppressor genes. DAC CDDO, 2-cyano-3,12-dioxooleana-1,9-dien(11)-28-oic acid; DFMO, difluoromethylornithine; FAS, fatty acid synthase; NSAID, non-steroidal anti-inflammatory drug; XSC, 1,4-phenylene-bis(methylene)-selenocyanate. (5-aza-2′-deoxycytidine) inhibits DNA methylation by reducing cytosine-DNA methyltransferase 1 activity. It inhibited NNK-induced lung tumorigenesis in two different mouse models, and its effects were potentiated by the histone deacetylase inhibitor phenylbutyrate 113, 114 . Collectively, the data reviewed here demonstrate that there are effective agents available to target tobacco smoke carcinogens, their numerous biological effects both during and after exposure, including tumour promotion and co-carcinogenesis, and inflammation. rationally constructed mixtures of selected agents should logically be effective in antagonizing lung carcinogenesis.
A mixture for chemoprevention The solid efficacy and low toxicity of PeITC-NAC and myo-inositol, along with evidence that they have different targets in lung carcinogenesis, suggest that a combination of these agents might be useful for chemoprevention of lung carcinogenesis in smokers transitioning to quitting and in ex-smokers.
The first goal of this study was to test the agents alone in different temporal sequences that reflect, to some extent, the situation in a smoker transitioning to quitting. No smoker would begin using chemopreventive agents at the same time as initiating smoking, yet most of the experiments described in the previous section, in which agents were tested during or before the carcinogen administration phase, reflected that unlikely situation. Therefore, we tested PeITC-NAC and myo-inositol, individually and in combination, on carcinogen-treated mice, starting 24 hours after the fourth or sixth carcinogen administration (FIG. 1) and continuing until the end of the experiment, 19 weeks after the final carcinogen administration. The results were compared to those obtained when the compounds were given for the entire experiment or only after carcinogen administration, the latter mimicking their use in ex-smokers. All treatments led to significant reductions in lung tumour multiplicity, except treatment with PeITC-NAC alone starting after the sixth carcinogen treatment or given after carcinogen treatment. For both agents, there was a significant trend for increased reduction in lung tumour multiplicity after longer durations of treatment. When combining PeITC-NAC and myo-inositol, we used non-toxic doses at which the individual compounds significantly reduced lung tumour multiplicity. In general, the mixture of PeITC-NAC plus myo-inositol was more effective than either agent alone, and when all results were combined the combination was significantly more effective, with the combined efficacy being roughly additive 36 . These positive results set the stage for a more detailed investigation of the mixture of PeITC-NAC plus myoinositol. Toxicity studies established doses of PeITC-NAC that were non-toxic, except for the presence of eosinophilic granules in the bladder mucosa. The mixture of PeITC-NAC plus myo-inositol, when given from the 50% point of carcinogen administration until termination at 44 weeks, inhibited lung tumour multiplicity by 46-72% (depending on the dose), and by 32% when given in the post-carcinogen phase alone. All of these decreases were significant. There was also a significant reduction of up to 75% in adenocarcinoma formation by PeITC-NAC plus myo-inositol given from the 50% time point, and a significant 53% reduction when given post-carcinogen only. A photograph of typical mouse lungs from this study is shown in FIG. 3 (REF. 37 ). Parallel mechanistic studies demonstrated that the observed inhibition of lung tumorigenesis was attributable in part to inhibition of cell proliferation and induction of apoptosis. Treatment of mice with NNK plus BaP together caused increased phosphorylation of Akt and BCL2 antagonist of cell death (BAD), resulting in loss of its proapoptotic function, and these effects were inhibited by both PeITC-NAC and myo-inositol. Furthermore, proteomic analysis demonstrated that PeITC-NAC plus myo-inositol altered the levels of several crucial proteins in lung tumours from these mice 66 .
Collectively, these results demonstrate that the mixture of PeITC-NAC and myo-inositol is effective and can be advanced to the next stage of development.
From animal models to clinical trials
There are currently no chemopreventive agents for which efficacy against lung cancer has been demonstrated in clinical trials. All trials to date have yielded negative or even damaging results, as reviewed previously 22, 44, [115] [116] [117] [118] [119] [120] . Potential reasons for these negative results have been discussed extensively in previous reviews, but one major explanation is a violation in some cases of the most important rule: ensuring efficacy in laboratory animal models of lung carcinogenesis. In this section, we summarize some current clinical trials derived at least partially from the efficacy studies summarized in TABLE 1 and discussed above. These trials are described, using the search terms lung cancer and prevention, on the US National Cancer Institute's Clinical Trials web site: (see Further information). Trial designs for chemoprevention have also been reviewed 121 . A Phase II trial of PeITC is designed to determine, as the primary end point, whether PeITC has the same inhibitory properties on the metabolic activation of NNK in smokers as it does in rats, in a randomized, placebocontrolled trial. As a secondary end point, the effects of GSTM1 plus GSTT1 null status on the inhibitory activity of PeITC will be determined. In an associated longer-term study, the effects of PeITC on biomarkers of bronchial epithelial cell apoptosis and proliferation will be assessed. This trial finds further support from the results of two nested case-control studies demonstrating a significant relationship of the NNK biomarker total NNAL to lung cancer 122, 123 . Lam and co-workers obtained some evidence for regression of pulmonary dysplasia in subjects enrolled in a Phase I trial of myo-inositol 58 . This observation, together with the numerous efficacy studies described above and the established low toxicity of myo-inositol, led to a Phase II study of the efficacy of myo-inositol treatment versus a placebo in current and former smokers. The primary end point in this study is the reversion of bronchial dysplasia. Secondary end points include the identification of biomarkers of proliferation, apoptosis and angiogenesis in bronchial biopsy samples and biomarkers of inflammation in bronchial lavage and plasma samples.
A Phase II study with green tea will examine the effects of high doses of green tea (four 12 oz (341 ml) servings per day) or polyphenon e (four capsules per day) on biomarkers of oxidative damage in former smokers with CoPD, as the primary end point. Secondary end points include investigating body antioxidant status and antioxidant enzymes, and markers of apoptosis and proliferation in induced sputum. A second Phase II study of polyphenon e will examine efficacy and safety in current or former smokers with bronchial dysplasia and increased inflammatory load, as measured by levels of C-reactive protein. Secondary end points in this trial include biomarkers of oxidative stress, inflammation, apoptosis, aberrant DNA methylation, phase I and II enzyme expression, and proliferation.
A Phase II trial of sulindac will examine its effects (versus those of a placebo) on the histological grade of bronchial dysplasia, as determined in bronchoscopy examinations in smokers or former smokers. Secondary end points include determination of the number of dysplastic lesions before and after treatment and changes in biomarkers of the arachidonic acid pathway, as well as biomarkers of apoptosis and proliferation.
It is notable that there are no ongoing trials of mixtures of chemopreventive agents. This contrasts with a major theme of this article. The principal that mixtures of chemoprevention agents can be effective in clinical trials without serious toxicity has recently been established in a study of sulindac and DFmo to prevent recurrent colon adenomas 124 .
Treatment of smokers
The primary concern about the use of a chemopreventive agent against lung carcinogenesis is that it may give smokers a false sense of security. They may feel that smoking is 'safe' or significantly 'safer' , which will result in their continuing to smoke, relapsing to smoking or even initiating smoking. However, providing treatments to those individuals who continue to practice behaviours that put them at high risk for disease is not uncommon. For example, statins or anithypertensives are not withheld from patients with poor eating habits and a sedentary lifestyle, even if health care providers may be concerned that the use of these agents might contribute to the obesity epidemic. A similar analogy can be made with chemopreventive agents for smoking.
What is clear is that safeguards must be in place so that smokers are not misled or given the misconception that using a chemopreventive agent is the solution and makes smoking safe. A chemopreventive agent may reduce the risk of one disease, such as lung cancer; however, many other diseases are associated with cigarette smoking, including other cancers, heart disease and lung disease 125 . Therefore, smoking cessation must be the primary goal for and message to the patient. Although some researchers have advocated the use of chemopreventive agents for only those who want to quit smoking, the rate of success is low, and smokers often transition in and out of quitting 126 and in and out of being motivated to quit 127 , making it difficult to determine who should and should not receive chemopreventive treatment if the prescription criterion is based only on whether or not the smoker is ready to quit. Therefore, we think that smokers uninterested in quitting or unable to quit should be considered for chemopreventive therapy, although this approach has been barely recognized by those interested in tobacco harm-reduction strategies 128 . In addition to smokers, depending on the mechanism of action, successful quitters or former smokers can potentially benefit from chemopreventive agents.
According to the principles that are used to guide proposed public health interventions, it is crucial that the intervention reduces rather than increases morbidity and mortality on a population level, that it results in no more harm than there is already, that the risks and benefits are distributed equitably across different populations (no population benefits at the expense of another) and that the autonomous choices of individuals and communities are respected 129, 130 . These are the criteria by which chemopreventive therapies for tobacco-related diseases should be evaluated.
Conclusions
Despite of the lack of success in chemoprevention of lung carcinogenesis so far, there is reason to be optimistic. The data summarized here clearly demonstrate that there are numerous agents that are effective inhibitors of lung carcinogenesis in animal models, and that these agents operate by diverse mechanisms. It is likely that success will depend on judicious use of a combination of these agents, because cellular damage from years of cigarette smoking is both complex and extensive. Single agents that target single pathways or carcinogens are not likely to be successful. We need to target the multiple activities of cigarette smoke: its carcinogens and toxicants and their downstream, tumour-promoting and inflammatory effects. The successful mixture will be assembled stepwise and driven by efficacy testing in one or more of the animal models described here. This chemopreventive mixture will have minimal toxicity in animal models and humans, which might be achievable by using naturally occurring compounds in doses no greater than those present in common foods such as vegetables. All smokers should be considered for chemoprevention of lung carcinogenesis, but with the strong message that no chemopreventive agent makes smoking safe. In addition, chemoprevention should be given in the context of providing smoking cessation advice and assistance. ex-smokers should also benefit from chemoprevention. Although not discussed here, genetic, molecular and phenotypic biomarkers could be used to select those subjects at highest risk for lung cancer, and treatment should be delivered promptly to such individuals. Although avoidance of tobacco products is the surest way to decrease lung cancer risk, chemoprevention promises to be a useful adjunct strategy.
